First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical Cancer

Abstract

Conflicts of interest and sources of funding: The authors have no conflicts of interest to declare. This study has been supported by SOFIE by the provision of precursors for FAPI synthesis. A.D. discloses research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, SOFIE and Eisai; Speaker Honorary and/or Advisory Boards fees from Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk; Invicro Stock from Siemens Healthineers, Lantheus Holding, and a patent pending for 18 F-PSMA7 (PSMA PET imaging tracer). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent to undergo imaging and RT was obtained from all individual participants included in the study. The local institutional review board waived requirement to obtain consent for retrospective data analysis.

Novel 68Ga-Labeled Pyridine-Based Fibroblast Activation Protein-Targeted Tracers with High Tumor-to-Background Contrast

“…However, [ 68 Ga]Ga-FAPI-04 has a relatively short tumor retention, making it unsuitable for theranostic purposes. Therefore, many other promising FAP-targeted radioligands are being developed and some are being evaluated clinically, such as [ 177 Lu]Lu-FAP-2286 [ 25 ] and [ 68 Ga]Ga-FAPI-46 ( Figure 1 ) [ 26 ].…”

FAPI-Negative FDG-Avid Metastatic Relapse of Breast Cancer on PET/CT

“…However, 18 F-FDG uptake decreases in luminal A and invasive lobular carcinoma, causing false-negative results in the assessment of disease stage 4,5 . 68 Ga-FAPI PET/CT has recently emerged as a potential imaging modality, which could have a role in different clinical situations, including BC 6–11 . Kömek et al 12 demonstrated the superiority of 68 Ga-FAPI-04 PET/CT over 18 F-FDG PET/CT in predominantly ER + primary tumors and in detecting LNs and distant metastases.…”

“…4,5 68 Ga-FAPI PET/CT has recently emerged as a potential imaging modality, which could have a role in different clinical situations, including BC. [6][7][8][9][10][11] Kömek et al 12 demonstrated the superiority of 68 Ga-FAPI-04 PET/CT over 18 F-FDG PET/CT in predominantly ER + primary tumors and in detecting LNs and distant metastases. In contrast to them, Ding et al 13 revealed that the sensitivity of 68 Ga-FAPI-04 PET/CT decreased at the advanced stage of BC.…”

Pulmonary Cryptococcosis

“…Ga-FAPI PET/CT showed potential in the detection of tumors. [1][2][3][4] However, false-positive uptake of FAPI has been reported in nonmalignant lesions, 5,6 including cryptococcosis and tuberculosis. 7,8 This case re-emphasizes that pulmonary cryptococcosis manifests as increased FAPI uptake.…”

“…However, the histopathologic result revealed the diagnosis of pulmonary cryptococcosis ( E ) and hepatic adenocarcinoma ( F ). Many previous studies have reported that 68 Ga-FAPI PET/CT showed potential in the detection of tumors 1–4 . However, false-positive uptake of FAPI has been reported in nonmalignant lesions, 5,6 including cryptococcosis and tuberculosis 7,8 .…”